Badrilla Ltd is a UK based biotechnology company founded in 2003 that makes exceptional antibodies to cardiovascular protein and phospho-protein targets. Working with outstanding academic collaborators, we are developing new calibration technologies, which will enable the performance of genuinely quantitative western blotting. Badrilla Ltd has always strived to make positive contributions to the antibody market via thorough product validation and honest data presentation.
Tuesday, 28 August 2018
ACYL PEG EXCHANGE – AN IMPORTANT ADVANCE IN THE PALMITOYLATION TOOLBOX
Dr. M.S. Bhogal
There have been many recent advances in methodologies to detect the only reversible lipidation reaction of proteins, S-palmitoylation. This fatty acyl post translational modification has gained great interest in the research community as it is increasingly recognised as important in both health and in disease areas such as
Cancer – A number of liver1 and gastric2 cancers are associated with loss of function mutations of the DHHC class of palmitoyl acyl transferase (PAT) enzymes. [Click here for Badrilla Blog article]
Cardiovascular disease – Heart contraction is determined by calcium cycling within heart cells and this process is regulated by a plethora of channels and transporters. Abnormal S-palmitoylation of key channels has been associated with cardiac disease3. [Click here for Badrilla Blog article]
Neurodegenerative diseases – Recent evidence suggests an increase in S-palmitoylation of the scaffold protein PSD-95 may contribute to the NMDA mediated excitotoxicity that is associated with Huntingdon’s disease4. [Click here for Badrilla Blog article]
In this article I will briefly examine the development of the acyl exchange methodologies used by researchers to measure palmitoylation. I will focus in particular on the recently published Acyl PEG Exchange (APE) 5/Acyl PEGyl Gel Shift(APEGS) 6 assay, paying particular attention to the advantages it offers scientists interested in exploring palmitoylation.